What Is Acular LS and how is it used?
Acular LS is a prescription medicine used to treat the symptoms of Allergic Conjunctivitis, Pain, Inflammation, Burning and Stinging of the Eye after surgery or as caused by seasonal allergies. Acular LS may be used alone or with other medications.
Acular LS belongs to a class of drugs called Ophthalmic NSAIDs younger than 2 years of age.
It is not known if Acular LS is safe and effective in children.
What are the possible side effects of Acular LS?
Acular LS may cause serious side effects including:
- difficulty breathing,
- swelling of your face, lips, tongue, or throat,
- severe burning, stinging, or itching or eyes,
- a wound that will not heal,
- eye pain,
- redness of the eye,
- watering of the eye,
- vision changes,
- increased sensitivity to light,
- white patches on your eyes, and
- crusting or drainage from your eyes
Get medical help right away, if you have any of the symptoms listed above.
The most common side effects of Acular LS include:
- mild eye pain, stinging, or redness,
- blurred vision,
- watery eyes,
- swollen or puffy eyelids, and
Tell the doctor if you have any side effect that bothers you or that does not go away.
These are not all the possible side effects of Acular LS. For more information, ask your doctor or pharmacist.
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
ACULAR LS™ (ketorolac tromethamine ophthalmic solution) 0.4% is a member of the pyrrolo-pyrrole group of nonsteroidal anti-inflammatory drugs (NSAIDs) for ophthalmic use.
Structural and Molecular Formula:
Chemical Name: (±)-5-Benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid, compound with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1)
Contains: Active: ketorolac tromethamine 0.4%. Preservative: benzalkonium chloride 0.006%. Inactives:sodium chloride; edetate disodium 0.015%; octoxynol 40; purified water; and hydrochloric acid and/or sodium hydroxide to adjust the pH.
ACULAR LS™ (ketorolac tromethamine ophthalmic solution) ophthalmic solution is supplied as a sterile isotonic aqueous 0.4% solution, with a pH of approximately 7.4. ACULAR LS™ ophthalmic solution is a racemic mixture of R-(+) and S-(-)-ketorolac tromethamine. Ketorolac tromethamine may exist in three crystal forms. All forms are equally soluble in water. The pKa of ketorolac is 3.5. This white to off-white crystalline substance discolors on prolonged exposure to light. The osmolality of ACULAR LS™ (ketorolac tromethamine ophthalmic solution) ophthalmic solution is approximately 290 mOsml/kg.
3 pharmacies near 20147 have coupons for Acular (Brand Names:Acular LS for 5ML of 0.5%)
Est. Regular Price
with free coupon
Est. Regular Price
with free coupon
Est. Regular Price
with free coupon
DOSAGE AND ADMINISTRATION
The recommended dose of ACULAR LS™ (ketorolac tromethamine ophthalmic solution) ophthalmic solution is one drop four times a day in the operated eye as needed for pain and burning/stinging for up to 4 days following corneal refractive surgery.
Ketorolac tromethamine ophthalmic solution has been safely administered in conjunction with other ophthalmic medications such as antibiotics, beta blockers, carbonic anhydrase inhibitors, cycloplegics, and mydriatics.
ACULAR LS™ (ketorolac tromethamine ophthalmic solution) 0.4% is supplied sterile in an opaque white LDPE plastic bottle with a white dropper with a gray high impact polystyrene (HIPS) cap as follows:
5 mL in 10 mL bottle- NDC 0023-9277-05
Note: Store at 15°C - 25°C (59°F- 77°F).
This product is manufactured and distributed by ALLERGAN under license from its developer, Roche Palo Alto LLC, Palo Alto, California, U.S.A. May 2003. FDA Rev date: 12/1/2008
The most frequently reported adverse reactions for ACULAR LS™ (ketorolac tromethamine ophthalmic solution) ophthalmic solution occurring in approximately 1 to 5% of the overall study population were conjunctival hyperemia, corneal infiltrates, headache, ocular edema and ocular pain.
The most frequent adverse events reported with the use of ketorolac tromethamine ophthalmic solutions have been transient stinging and burning on instillation. These events were reported by 20% - 40% of patients participating in these other clinical trials.
Other adverse events occurring approximately 1% - 10% of the time during treatment with ketorolac tromethamine ophthalmic solutions included allergic reactions, corneal edema, iritis, ocular inflammation, ocular irritation, ocular pain, superficial keratitis, and superficial ocular infections.
Clinical Practice: The following events have been identified during postmarketing use of ketorolac tromethamine ophthalmic solutions in clinical practice. Because they are reported voluntarily from a population of unknown size, estimates of frequency cannot be made The events, which have been chosen for inclusion due to either their seriousness, frequency of reporting, possible causal connection to topical ketorolac tromethamine ophthalmic solutions or a combination of these factors, include corneal erosion, corneal perforation corneal thinning and epithelial breakdown (see PRECAUTIONS, General).
No information provided.
There is the potential for cross-sensitivity to acetylsalicylic acid, phenylacetic acid derivatives, and other nonsteroidal anti-inflammatory agents. Therefore, caution should be used when treating individuals who have previously exhibited sensitivities to these drugs.
With some nonsteroidal anti-inflammatory drugs there exists the potential for increased bleeding time due to interference with thrombocyte aggregation. There have been reports that ocularly applied nonsteroidal anti-inflammatory drugs may cause increased bleeding of ocular tissues (including hyphemas) in conjunction with ocular surgery.
All topical nonsteroidal anti-inflammatory drugs (NSAIDs), including ketorolac tromethamine ophthalmic solution, may slow or delay healing. Topical corticosteroids are also known to slow or delay healing. Concomitant use of topical NSAIDS and topical steroids may increase the potential for healing problems.
Use of topical NSAIDs may result in keratitis. In some susceptible patients, continued use of topical NSAIDs may result in epithelial breakdown, corneal thinning corneal erosion, corneal ulceration or corneal perforation. These events may be sight threatening. Patients with evidence of corneal epithelial breakdown should immediately discontinue use of topical NSAIDs and should be closely monitored for corneal health.
Postmarketing experience with topical NSAIDs suggests that patients with complicated ocular surgeries, corneal denervation, corneal epithelial defects, diabetes mellitus, ocular surface diseases (e.g , dry eye syndrome), rheumatoid arthritis, or repeat ocular surgeries within a short period of time may be at increased risk for corneal adverse events which may become sight threatening. Topical NSAIDs should be used with caution in these patients.
Postmarketing experience with topical NSAIDs also suggests that use more than 24 hours prior to surgery or use beyond 14 days post-surgery may increase patient risk for the occurrence and severity of corneal adverse events.
It is recommended that ACULAR LS™ (ketorolac tromethamine ophthalmic solution) ophthalmic solution be used with caution in patients with known bleeding tendencies or who are receiving other medications, which may prolong bleeding time.
Carcinogenesis, Mutagenesis, Impairment of Fertility
Ketorolac tromethamine was neither carcinogenic in rats given up to 5 mg/kg/day orally for 24 months (156 times the maximum recommended human topical ophthalmic dose, on a mg/kg basis, assuming 100% absorption in humans and animals) nor in mice given 2 mg/kg/day orally for 18 months (62.5 times the maximum recommended human topical ophthalmic dose, on a mg/kg basis, assuming 100% absorption in humans and animals).
Ketorolac tromethamine was not mutagenic in vitro in the Ames assay or in forward mutation assays. Similarly, it did not result in an in vitro increase in unscheduled DNA synthesis or an in vivo increase in chromosome breakage in mice. However, ketorolac tromethamine did result in an increased incidence in chromosomal aberrations in Chinese hamster ovary cells.
Ketorolac tromethamine did not impair fertility when administered orally to male and female rats at doses up to 280 and 499 times the maximum recommended human topical ophthalmic dose, respectively, on a mg/kg basis, assuming 100% absorption in humans and animals.
Teratogenic Effects: Pregnancy Category C
Ketorolac tromethamine, administered during organogenesis, was not teratogenic in rabbits or rats at oral doses up to 112 times and 312 times the maximum recommended human topical ophthalmic dose, respectively on a mg/kg basis assuming 100% absorption in humans and animals. When administered to rats after Day 17 of gestation at oral doses up to 46 times the maximum recommended human topical ophthalmic dose on a mg/kg basis, assuming 100% absorption in humans and animals, ketorolac tromethamine resulted in dystocia and increased pup mortality. There are no adequate and well-controlled studies in pregnant women. ACULAR LS™ (ketorolac tromethamine ophthalmic solution) ophthalmic solution should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Because of the known effects of prostaglandin-inhibiting drugs on the fetal cardiovascular system (closure of the ductus arteriosus), the use of ACULAR LS™ ophthalmic solution during late pregnancy should be avoided.
Caution should be exercised when ACULAR LS™ (ketorolac tromethamine ophthalmic solution) ophthalmic solution is administered to a nursing woman.
Safety and effectiveness of ketorolac tromethamine in pediatric patients below the age of 3 have not been established.
No overall differences in safety or effectiveness have been observed between elderly and younger patients.
No information provided.
ACULAR LS™ (ketorolac tromethamine ophthalmic solution) ophthalmic solution is contraindicated in patients with previously demonstrated hypersensitivity to any of the ingredients in the formulation.
Mechanism of Action
Ketorolac tromethamine is a nonsteroidal anti-inflammatory drug which, when administered systemically, has demonstrated analgesic, anti-inflammatory, and anti-pyretic activity. The mechanism of its action is thought to be due to its ability to inhibit prostaglandin biosynthesis. Ketorolac tromethamine given systemically does not cause pupil constriction.
One drop (0.05 mL) of 0.5% ketorolac tromethamine ophthalmic solution was instilled into one eye and one drop of vehicle into the other eye TID in 26 normal subjects. Only 5 of 26 subjects had a detectable amount of ketorolac in their plasma (range 10.7 to 22 5 ng/mL) at day 10 during topical ocular treatment. When ketorolac tromethamine 10 mg is administered systemically every 6 hours, peak plasma levels at steady state are around 960 ng/mL.
In two double-masked, multi-centered, parallel-group studies, 313 patients who had undergone photorefractive keratectomy received ACULAR LS™ (ketorolac tromethamine ophthalmic solution) 0.4% or its vehicle QID for up to 4 days. Significant differences favored ACULAR LS™ (ketorolac tromethamine ophthalmic solution) for the reduction of ocular pain and burning/stinging following photorefractive keratectomy surgery.
Results from clinical studies indicate that ketorolac tromethamine has no significant effect upon intraocular pressure.
ACULAR LS™ (ketorolac tromethamine ophthalmic solution) ophthalmic solution should not be administered while wearing contact lenses.
Eye Health Resources
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.